Peptide and Oligonucleotide CDMO Market Summary

As per Market Research Future analysis, the Peptide and Oligonucleotide CDMO Market Size was estimated at 7.805 USD Billion in 2024. The Peptide and Oligonucleotide CDMO industry is projected to grow from 9.038 USD Billion in 2025 to 39.19 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 15.8% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Peptide and Oligonucleotide CDMO market is experiencing robust growth driven by technological advancements and increasing demand for personalized medicine.

The North American region remains the largest market for peptide and oligonucleotide CDMOs, reflecting a strong biopharmaceutical sector.
Asia-Pacific is emerging as the fastest-growing region, fueled by rising investments in biotechnology and healthcare infrastructure.
Peptides dominate the market as the largest segment, while oligonucleotides are recognized as the fastest-growing segment due to their applications in targeted therapies.
Key market drivers include the increasing prevalence of chronic diseases and advancements in biopharmaceutical research, which are propelling demand for innovative therapies.

Market Size & Forecast

2024 Market Size	7.805 (USD Billion)
2035 Market Size	39.19 (USD Billion)
CAGR (2025 - 2035)	15.8%

Major Players

Lonza (CH), WuXi AppTec (CN), Boehringer Ingelheim (DE), Sartorius (DE), Thermo Fisher Scientific(US), CordenPharma (DE), PeptiDream (JP), AstraZeneca (GB), Evonik Industries (DE)

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

Peptide and Oligonucleotide CDMO Market Trends

The Peptide and Oligonucleotide CDMO Market is currently experiencing a notable evolution, driven by the increasing demand for advanced therapeutics and personalized medicine. This market encompasses a range of services, including the development and manufacturing of peptides and oligonucleotides, which are crucial components in drug discovery and development. As pharmaceutical companies seek to enhance their product pipelines, the reliance on contract development and manufacturing organizations (CDMOs) has intensified. This trend suggests a shift towards outsourcing, allowing companies to focus on core competencies while leveraging the expertise of specialized providers. Moreover, the Peptide and Oligonucleotide CDMO Market appears to be influenced by technological advancements in synthesis and purification processes. Innovations in these areas are likely to improve efficiency and reduce costs, making it more feasible for smaller biotech firms to enter the market. Additionally, regulatory frameworks are evolving, which may facilitate faster approvals for new therapies. As a result, the landscape of the Peptide and Oligonucleotide CDMO Market is poised for growth, with an emphasis on collaboration between CDMOs and pharmaceutical companies to meet the rising expectations of the healthcare sector.

Rising Demand for Personalized Medicine

The trend towards personalized medicine is gaining momentum, as patients increasingly seek treatments tailored to their specific genetic profiles. This shift is prompting pharmaceutical companies to invest in the development of targeted therapies, thereby driving the need for specialized CDMO services that can efficiently produce customized peptides and oligonucleotides.

Technological Innovations in Manufacturing

Advancements in manufacturing technologies are reshaping the Peptide and Oligonucleotide CDMO Market. Enhanced synthesis methods and purification techniques are streamlining production processes, which may lead to higher yields and reduced costs. These innovations are particularly beneficial for smaller companies looking to compete in a rapidly evolving landscape.

Regulatory Changes and Compliance

The regulatory environment surrounding the Peptide and Oligonucleotide CDMO Market is undergoing significant changes. Stricter compliance requirements are emerging, which could impact how CDMOs operate. However, these changes may also create opportunities for CDMOs that can adapt quickly and demonstrate their commitment to quality and safety.

Peptide and Oligonucleotide CDMO Market Drivers

Regulatory Support for Biologics

The evolving regulatory landscape is providing substantial support for the development of biologics, including peptides and oligonucleotides, thereby impacting the Peptide and Oligonucleotide CDMO Market. Regulatory agencies are increasingly recognizing the therapeutic potential of these compounds and are streamlining approval processes. This supportive environment encourages pharmaceutical companies to invest in the development of peptide and oligonucleotide-based therapies. Recent regulatory initiatives aimed at expediting the review of biologics are likely to enhance the attractiveness of these therapies. As a result, CDMOs are positioned to play a critical role in navigating the regulatory complexities, ensuring compliance, and facilitating the timely market entry of innovative products.

Growing Investment in Biotechnology

The surge in investment within the biotechnology sector is a crucial driver for the Peptide and Oligonucleotide CDMO Market. Venture capital and private equity funding have been directed towards biotechnology firms focusing on peptide and oligonucleotide therapeutics. This influx of capital is facilitating research and development activities, enabling companies to explore new therapeutic avenues. Recent statistics reveal that biotechnology investments have reached unprecedented levels, indicating a robust interest in innovative drug development. As biotechnology firms seek to leverage the capabilities of CDMOs for efficient manufacturing processes, the Peptide and Oligonucleotide CDMO Market is poised for significant expansion, driven by this financial momentum.

Rising Demand for Targeted Therapies

The increasing demand for targeted therapies is reshaping the landscape of the Peptide and Oligonucleotide CDMO Market. Patients and healthcare providers are increasingly favoring treatments that offer precision and reduced side effects. Peptides and oligonucleotides are particularly well-suited for targeted therapies due to their ability to interact specifically with biological targets. Market analysis suggests that the shift towards personalized medicine is driving pharmaceutical companies to invest in the development of these therapies. Consequently, CDMOs specializing in peptide and oligonucleotide production are becoming vital players in the market, as they provide the necessary infrastructure and expertise to meet this growing demand.

Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is a pivotal driver for the Peptide and Oligonucleotide CDMO Market. As these conditions become more prevalent, there is a corresponding demand for innovative therapeutic solutions, including peptide and oligonucleotide-based drugs. According to recent data, the global burden of chronic diseases is expected to increase, necessitating advanced treatment options. This trend compels pharmaceutical companies to collaborate with contract development and manufacturing organizations (CDMOs) to expedite the development and production of these specialized therapies. Consequently, the Peptide and Oligonucleotide CDMO Market is likely to experience substantial growth as it caters to the urgent need for effective treatments.

Advancements in Biopharmaceutical Research

The ongoing advancements in biopharmaceutical research are significantly influencing the Peptide and Oligonucleotide CDMO Market. Innovations in drug discovery and development methodologies, particularly in the fields of genomics and proteomics, are leading to the identification of novel therapeutic targets. This evolution is fostering an environment where peptides and oligonucleotides are increasingly recognized for their therapeutic potential. Market data indicates that the biopharmaceutical sector is projected to expand, with a notable increase in the number of peptide and oligonucleotide-based drugs entering clinical trials. As a result, CDMOs are becoming essential partners in the development process, providing the necessary expertise and resources to bring these innovative therapies to market.

Market Segment Insights

By Type: Peptides (Largest) vs. Oligonucleotides (Fastest-Growing)

In the Peptide and Oligonucleotide CDMO market, Peptides hold the largest market share, benefiting from their established applications in pharmaceuticals, especially in therapeutics for chronic diseases and oncology. Peptides have been widely adopted due to their efficacy, lower side effect profiles, and the increasing prevalence of conditions treatable with peptide-based therapies. In contrast, Oligonucleotides are seeing rapid growth as they gain recognition for their role in gene therapy and personalized medicine, positioning themselves as a critical player in the evolving market landscape. The growth trends within this segment are driven by advancements in technology and an increasing focus on biopharmaceutical development. The ongoing research into gene editing techniques and a rise in funding for genetic therapies are accelerating the adoption of Oligonucleotides. Additionally, the market is experiencing heightened interest in personalized medicine, leading to a surge in demand for tailored therapeutic options, particularly in the Oligonucleotide sector. As a result, while Peptides remain dominant, Oligonucleotides are emerging as a key growth driver in the CDMO space.

Peptides (Dominant) vs. Oligonucleotides (Emerging)

Peptides are characterized by their high stability, ease of synthesis, and wide range of applications in the biopharmaceutical sector. They are increasingly utilized in drug development due to their specificity and ability to interact with biological targets effectively. The market for peptides is mature, yet continuously innovating, as new methods in synthesis and purification enhance their production efficiency. On the other hand, Oligonucleotides are emerging as a pivotal technology in therapeutic science, primarily due to advancements in RNA-based therapies, such as siRNA and antisense oligonucleotides. Their ability to directly target specific genes offers extraordinary potential for treating genetic disorders and cancers, causing a shift towards personalized and precise medical strategies.

By Application: Pharmaceuticals (Largest) vs. Diagnostics (Fastest-Growing)

In the Peptide and Oligonucleotide CDMO market, the Pharmaceuticals application holds the largest share, driven by the continuous demand for innovative therapeutic solutions. This segment encompasses a range of applications including drug development and personalized medicine, making it a critical area for the growth of CDMO services. Diagnostics is witnessing rapid growth, fueled by advancements in biotechnology and the increasing necessity for precision medicine, reflecting a shift toward predictive diagnostics and biomarker discovery.

Pharmaceuticals: Dominant vs. Diagnostics: Emerging

The Pharmaceuticals application remains dominant in the Peptide and Oligonucleotide CDMO market, characterized by a robust pipeline of biologics and specialty drugs. Companies focus on leveraging peptides and oligonucleotides to develop targeted therapies, often requiring complex manufacturing processes and stringent quality controls. In contrast, the Diagnostics application is emerging rapidly, benefiting from innovations in genetic testing and personalized diagnostics. This segment emphasizes the need for high-throughput production capabilities and rapid turnaround times, which are essential for successfully addressing the evolving demands in healthcare and enabling timely decision-making in clinical settings.

By Synthesis Route: Solid-phase Synthesis (Largest) vs. Automated Synthesis (Fastest-Growing)

In the Peptide and Oligonucleotide CDMO Market, Solid-phase Synthesis holds the largest market share due to its established methodology and efficacy in producing high-quality peptides. This segment continues to be favored for its scalability and efficiency, particularly in large-scale productions. Solution-phase Synthesis, while also significant, accounts for a smaller share as it often involves longer processing times and higher resource requirements. Automated Synthesis is emerging rapidly, driven by advancements in technology and increased demand for high-throughput capabilities.

Solid-phase Synthesis (Dominant) vs. Automated Synthesis (Emerging)

Solid-phase Synthesis is predominantly utilized in the Peptide and Oligonucleotide CDMO Market, valued for its straightforward process and efficiency in handling complex peptide sequences. This synthesis method stands out for its ability to streamline production with minimal side reactions, making it the go-to choice for large-scale manufacturing. On the other hand, Automated Synthesis represents an emerging trend, leveraging innovative technology to enhance productivity and reduce manual labor. As regulatory demands increase and the need for rapid delivery of oligonucleotides grows, Automated Synthesis is becoming increasingly significant, offering flexibility and reliability that align with modern pharmaceutical needs.

By Scale: Commercial (Largest) vs. Preclinical (Fastest-Growing)

In the Peptide and Oligonucleotide CDMO Market, the commercial scale segment currently dominates market share, signifying the established players and their ability to meet extensive manufacturing demands. The preclinical segment, in contrast, is experiencing rapid growth, fueled by an increasing number of startups focusing on innovative therapeutic solutions. This shift reflects changing priorities in pharmaceutical developments and a strong pipeline of projects awaiting progress into clinical stages. The growth trends within these segments are driven by a surge in R&D investments aimed at developing novel therapeutics, particularly in the fields of oncology and rare diseases. Regulatory advancements and the heightened emphasis on personalized medicine further accelerate the pace for preclinical research. As the pharmaceutical industry embraces the integrative capabilities of peptides and oligonucleotides, a broader acceptance and demand for commercial scale production is projected, augmenting competition among CDMOs.

Commercial (Dominant) vs. Preclinical (Emerging)

The commercial scale segment of the Peptide and Oligonucleotide CDMO Market showcases its dominance, characterized by established manufacturing processes and a dependable supply chain. Companies at this scale possess the necessary infrastructure and expertise to handle large-scale production efficiently. Conversely, the preclinical segment emerges as a crucial area of growth, with many biotech companies leveraging cutting-edge technology to accelerate drug development timelines. This segment is characterized by agility and innovation, with numerous startups entering the market to explore novel therapeutic applications. The demand for flexible manufacturing capabilities and personalized treatments positions preclinical as a promising sector for CDMOs aiming to enter their manufacturing phase rapidly, thus serving the evolving needs of pharmaceutical developers.

Get more detailed insights about Peptide and Oligonucleotide CDMO Market

Request Free Sample

Regional Insights

The Peptide and Oligonucleotide CDMO Market is segmented into North America, Europe, APAC, South America, and MEA. North America is the largest regional segment, accounting for over 40% of the global market in 2023. Europe is the second largest regional segment, followed by APAC. The APAC region is expected to grow at the highest CAGR during the forecast period, due to the increasing demand for peptides and oligonucleotides in the region.

The growth of the Peptide and Oligonucleotide CDMO Market is driven by several factors, including the increasing demand for peptides and oligonucleotides in the pharmaceutical and biotechnology industries, the rising prevalence of chronic diseases, and the growing adoption of personalized medicine.The market is also expected to benefit from the increasing number of government initiatives to support the development of new peptide and oligonucleotide-based therapies. The Peptide and Oligonucleotide CDMO Market is highly competitive, with a number of major players operating in the market. These players include Thermo Fisher Scientific, Lonza, Bachem, and PeptiDream.

The market is also characterized by a number of emerging players, who are offering innovative peptide and oligonucleotide-based products and services.

Peptide and Oligonucleotide CDMO Market Regional Image

Key Players and Competitive Insights

Major players in the Peptide and Oligonucleotide CDMO Market industry are focusing on expanding their product portfolio and geographical reach. They are also investing in research and development to develop new and innovative products. Leading Peptide and Oligonucleotide CDMO Market players are adopting various strategies such as mergers and acquisitions, partnerships, and collaborations to gain a competitive edge in the market. The Peptide and Oligonucleotide CDMO Market development is driven by factors such as increasing demand for peptide and oligonucleotide therapies, growing prevalence of chronic diseases, and technological advancements. The competitive landscape of the Peptide and Oligonucleotide CDMO Market is characterized by the presence of both established and emerging players.A leading company in the Peptide and Oligonucleotide CDMO Market is Thermo Fisher Scientific. The company offers a wide range of peptide and oligonucleotide synthesis services, as well as analytical and purification services. Thermo Fisher Scientific has a global presence and a strong customer base. The company is focused on providing high-quality products and services to its customers. Thermo Fisher Scientific is also investing in research and development to develop new and innovative products.A competitor company in the Peptide and Oligonucleotide CDMO Market is GeneCust. The company offers a range of peptide and oligonucleotide synthesis services, as well as analytical and purification services. GeneCust has a strong presence in the Asia-Pacific region and is expanding its global reach. The company is focused on providing cost-effective products and services to its customers. GeneCust is also investing in research and development to develop new and innovative products.

Key Companies in the Peptide and Oligonucleotide CDMO Market include

Industry Developments

The Peptide and Oligonucleotide CDMO Market is projected to reach USD 25.25 billion by 2035, exhibiting a CAGR of 15.8% during the forecast period.

Key factors driving market growth include increasing demand for personalized medicine, rising prevalence of chronic diseases, and advancements in gene editing technologies.Recent news developments include: In 2023, Thermo Fisher Scientific acquired PeproTech, a leading manufacturer of peptides and proteins, to strengthen its position in the CDMO market. In 2024, Lonza announced plans to invest CHF 1 billion in its Visp, Switzerland site to expand its CDMO capabilities for peptides and oligonucleotides. In 2025, Catalent acquired Paragon Bioservices, a provider of gene therapy and viral vector CDMO services, to enhance its offerings in the growing gene therapy market.These developments underscore the increasing demand for CDMO services in the peptide and oligonucleotide market, driven by the growing complexity and scale of drug development projects.

Future Outlook

Peptide and Oligonucleotide CDMO Market Future Outlook

The Peptide and Oligonucleotide CDMO Market is projected to grow at a 15.8% CAGR from 2025 to 2035, driven by increasing demand for personalized medicine and advancements in biomanufacturing technologies.

New opportunities lie in:

Expansion into emerging markets with tailored peptide therapies. Investment in automated synthesis platforms for cost efficiency. Development of novel oligonucleotide delivery systems for targeted therapies.

By 2035, the market is poised for robust growth, reflecting evolving therapeutic needs and technological advancements.

Market Segmentation

Peptide Oligonucleotide CDMO Market Type Outlook

Peptides
Oligonucleotides
Conjugates

Peptide Oligonucleotide CDMO Market Scale Outlook

Preclinical
Clinical
Commercial

Peptide Oligonucleotide CDMO Market Application Outlook

Pharmaceuticals
Diagnostics
Cosmetics

Peptide Oligonucleotide CDMO Market Synthesis Route Outlook

Solid-phase Synthesis
Solution-phase Synthesis
Automated Synthesis

Report Scope

Report Attribute/Metric	Details
Market Size 2022	5.82(USD Billion)
Market Size 2023	6.74(USD Billion)
Market Size 2035	25.25(USD Billion)
Compound Annual Growth Rate (CAGR)	15.8% (2025 - 2035)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2023
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2023
Market Forecast Units	USD Billion
Key Companies Profiled	Jubilant Holdist, Peptide International, CordenPharma International, Peptech, GenScript Biotech, Thermo Fisher Scientific, Catalent, BioSynthesis, Lonza Group, Auspeptides, Piramal Enterprises, Synpeptide Technologies, PolyPeptide Laboratories, Bachem Group, Wuxi AppTec
Segments Covered	Type, Application, Synthesis Route, Scale, Regional
Key Market Opportunities	Increased demand for personalized medicine Growing adoption of oligonucleotide therapeutics Advancements in gene editing technologies Expansion of peptide-based drug development Rising prevalence of chronic diseases.
Key Market Dynamics	Growing demand technological advancements increasing RampD investments strategic partnerships expanding applications
Countries Covered	North America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation for the Peptide and Oligonucleotide CDMO Market in 2035?

The projected market valuation for the Peptide and Oligonucleotide CDMO Market in 2035 is 39.19 USD Billion.

What was the market valuation for the Peptide and Oligonucleotide CDMO Market in 2024?

The market valuation for the Peptide and Oligonucleotide CDMO Market in 2024 was 7.805 USD Billion.

What is the expected CAGR for the Peptide and Oligonucleotide CDMO Market from 2025 to 2035?

The expected CAGR for the Peptide and Oligonucleotide CDMO Market during the forecast period 2025 - 2035 is 15.8%.

Which companies are considered key players in the Peptide and Oligonucleotide CDMO Market?

Key players in the Peptide and Oligonucleotide CDMO Market include Lonza, WuXi AppTec, Boehringer Ingelheim, Sartorius, and Thermo Fisher Scientific.

What are the projected valuations for the Peptide segment by 2035?

The projected valuation for the Peptide segment by 2035 is expected to reach 18.5 USD Billion.

How does the market for Oligonucleotides compare to that of Peptides in 2035?

By 2035, the market for Oligonucleotides is projected to reach 12.5 USD Billion, indicating a substantial growth compared to the Peptide segment.

What is the expected market size for the Clinical scale segment by 2035?

The expected market size for the Clinical scale segment by 2035 is projected to be 12.5 USD Billion.

What synthesis route is anticipated to dominate the Peptide and Oligonucleotide CDMO Market by 2035?

Automated Synthesis is anticipated to dominate the market, with a projected valuation of 16.69 USD Billion by 2035.

What applications are driving growth in the Peptide and Oligonucleotide CDMO Market?

The Pharmaceuticals application is driving growth, with a projected valuation of 18.5 USD Billion by 2035.

What is the projected valuation for the Commercial scale segment by 2035?

The projected valuation for the Commercial scale segment by 2035 is expected to reach 19.2 USD Billion.

Author

Author

Rahul Gotadki

Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment